Sutro Biopharma appoints Borgman as Chief Medical Officer
- Sutro Biopharma (NASDAQ:STRO) has appointed Anne Borgman, M.D., as Chief Medical Officer, effective February 28, 2023.
- Dr. Borgman, most recently served as Vice President and Therapeutic Area Lead, Oncology, Hematology, and Transplant, at Jazz Pharmaceuticals.
- Dr. Borgman brings over 20 years of oncology and hematology drug development experience to Sutro, including extensive regulatory experience in both the U.S. and Europe, leading to nine regulatory approvals.